Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: Results from the Dutch National ABC Register

Annals of the Rheumatic Diseases

Volumn 72, Issue 5, 2013, Pages 721-727

  Otten, Marieke H ^a   Prince, Femke H M ^a   Anink, Janneke ^a   Ten Cate, Rebecca ^b   Hoppenreijs, Esther P A H ^c   Armbrust, Wineke ^d   Koopman Keemink, Yvonne ^e   Van Pelt, Philomine A ^a   Kamphuis, Sylvia ^a   Gorter, Simone L ^f   Dolman, Koert M ^g   Swart, Joost F ^h   Van Den Berg, J Merlijn ⁱ   Wulffraat, Nico M ^h   Van Rossum, Marion A J ⁱ   Van Suijlekom Smit, Lisette W A ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF GRONINGEN   (Netherlands)

^e JULIANA CHILDREN S HOSPITAL   (Netherlands)

^f MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^g ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^h UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

ⁱ EMMA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; INFLIXIMAB; METHOTREXATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ADOLESCENT; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; ENTERITIS; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HUMAN; INJECTION SITE REACTION; JUVENILE RHEUMATOID ARTHRITIS; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHOOL CHILD; THORAX PAIN; TREATMENT DURATION; UROSEPSIS; UVEITIS;

ADOLESCENT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOCONJUGATES; IMMUNOGLOBULIN G; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; KAPLAN-MEIER ESTIMATE; MALE; NETHERLANDS; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR; REGISTRIES; TREATMENT OUTCOME;

EID: 84875921715     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2011-201060     Document Type: Article

References (21)

1. Tynjala P, Vahasalo P, Honkanen V, et al. Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis. Ann Rheum Dis 2009;68:552-7.
2. Southwood TR, Foster HE, Davidson JE, et al. Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients. Rheumatology (Oxford) 2011;50:189-95.
3. Otten MH, Prince FH, Armbrust W, et al. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis. JAMA 2011;306:2340-7.
4. Mpofu S, Fatima F, Moots RJ. Anti-TNF-alpha therapies: they are all the same (aren't they?). Rheumatology (Oxford) 2005;44:271-3. (Pubitemid 40361279)
5. Scallon B, Cai A, Solowski N, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002;301:418-26. (Pubitemid 34429950)
6. Nigrovic PA, Mannion M, Prince FH, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 2012;64:557-67.
7. Quartier P, Allantaz F, Cimaz R, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 2011;70:747-54.
8. Swart JF, Barug D, Mohlmann M, et al. The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis. Expert Opin Biol Ther 2010;10:1743-52.
9. Ruperto N, Quartier P, Wulffraat N, et al. A phase II study to evaluate dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum 2011;
10. Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008;371:998-1006. (Pubitemid 351389534)
11. Favalli EG, Arreghini M, Arnoldi C, et al. Anti-tumor necrosis factor alpha switching in rheumatoid arthritis and juvenile chronic arthritis. Arthritis Rheum 2004;51:301-2. (Pubitemid 38468719)
12. Katsicas MM, Russo RA. Use of infliximab in patients with systemic juvenile idiopathic arthritis refractory to etanercept. Clin Exp Rheumatol 2005;23:545-8. (Pubitemid 41447630)
13. Katsicas MM, Russo RA. Use of adalimumab in patients with juvenile idiopathic arthritis refractory to etanercept and/or infliximab. Clin Rheumatol 2009;28:985-8.
14. Nerome Y, Imanaka H, Nonaka Y, et al. Switching the therapy from etanercept to infliximab in a child with rheumatoid factor positive polyarticular juvenile idiopathic arthritis. Mod Rheumatol 2007;17:526-8.
15. Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) 2011;63:465-82.
16. Prince FH, Ferket IS, Kamphuis S, et al. Development of a web-based register for the Dutch national study on biologicals in JIA: www.ABC-register.nl. Rheumatology (Oxford) 2008;47:1413-16.
17. Giannini EH, Ruperto N, Ravelli A, et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202-9. (Pubitemid 27430130)
18. Wallace CA, Ruperto N, Giannini E. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004;31:2290-4. (Pubitemid 39453253)
19. Remy A, Avouac J, Gossec L, et al. Clinical relevance of switching to a second tumour necrosis factor-alpha inhibitor after discontinuation of a first tumour necrosis factor-alpha inhibitor in rheumatoid arthritis: a systematic literature review and meta-analysis. Clin Exp Rheumatol 2011;29:96-103.
20. Simonini G, Taddio A, Cattalini M, et al. Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care Res (Hoboken) 2011;63:612-18.
21. Curtis JR, Xie F, Chen L, et al. The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents. Ann Rheum Dis 2011;70:1401-6.